19 completed, 6 active not recruiting, 5 terminated, 3 recruiting. 13 Phase 2, 6 Not applicable, 5 Phase 3, 4 Phase 1, 1 Phase 4.
Follow Foundation Medicine: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC Cisplatin, Carboplatin, Pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 318 | 2025-06-13 | 2026-09-21 |
| Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation Evaluation of ctDNA using the F1T after 1 year of immunotherapy - Melanoma, Non-small Cell Lung Cancer | Not applicable | Active not recruiting | Massachusetts General Hospital | 39 | 2024-01-10 | 2026-08-17 |
| A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer FoundationOne® Liquid CDx Assay, Standard of Care Diagnostic Pathway - Metastatic Lung Cancer, Metastatic Gastrointestinal Cancer | Not applicable | Completed | Hoffmann-La Roche | 463 | 2023-09-14 | 2025-12-17 |
| Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients 5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule - Stage II Colon Cancer, Stage III Colon Cancer | Phase 2 | Suspended | Gruppo Oncologico del Nord-Ovest | 477 | 2023-05-17 | 2026-02-03 |
| Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations olaparib, enzalutamide, abiraterone acetate - Metastatic Castration-resistant Prostate Cancer | Phase 4 | Active not recruiting | AstraZeneca | 43 | 2022-07-29 | 2026-04-21 |
| NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer Pembrolizumab - Adenocarcinoma of the Colon | Phase 2 | Active not recruiting | University College, London | 88 | 2022-07-20 | 2026-09-14 |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib - Endometrial Cancer | Phase 1 / Phase 2 | Recruiting | Alliance Foundation Trials, LLC. | 148 | 2021-10-20 | 2026-04-01 |
| Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer Capecitabine, Talazoparib, Pembrolizumab - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Terminated | Bryan Schneider, MD | 52 | 2021-08-24 | 2025-05-31 |
| Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination Carboplatin, Paclitaxel, Bevacizumab - Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 1 / Phase 2 | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 290 | 2021-03-17 | 2021-08-27 |
| A Study to Examine the Value of Broad Agnostic Next Generation Sequencing (NGS) Panel Testing Versus Reimbursed Organ-directed NGS: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Center NGS testing - Metastatic Cancer, Local Tumor Invasion | Not applicable | Unknown | The Belgian Society of Medical Oncology | 1000 | 2020-10-09 | 2021-05-28 |
| TCF-001 TRACK (Target Rare Cancer Knowledge) Study FoundationOne CDx and FoundationOne Liquid CDx - Rare Cancers, Cholangiocarcinoma | Not applicable | Recruiting | TargetCancer Foundation | 400 | 2020-10-01 | 2026-05-26 |
| Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study Next generation sequencing - Adenocarcinoma of Lung, EGFR Activating Mutation | Unknown | Konkuk University Medical Center | 80 | 2019-09-30 | 2022-08-18 | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) Rucaparib, Nivolumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Terminated | pharmaand GmbH | 1 | 2019-08-23 | 2023-06-12 |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Alectinib, Vismodegib, Ipatasertib - Cancer of Unknown Primary Site | Phase 2 | Completed | Hoffmann-La Roche | 529 | 2018-07-10 | 2025-11-19 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Rucaparib - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Terminated | pharmaand GmbH | 97 | 2018-06-01 | 2023-06-09 |
| A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy Rucaparib, Nivolumab, Placebo Oral Tablet - Epithelial Ovarian Cancer, Primary Peritoneal | Phase 3 | Active not recruiting | pharmaand GmbH | 1097 | 2018-05-14 | 2025-06-24 |
| Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins Treatment recommendation - Metastatic Breast Cancer | Not applicable | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 200 | 2018-01-26 | 2026-06-08 |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel - Metastatic Castration Resistant Prostate Cancer | Phase 3 | Completed | pharmaand GmbH | 405 | 2017-06-13 | 2025-07-25 |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Chemotherapy, Rucaparib - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 3 | Completed | pharmaand GmbH | 349 | 2017-03-01 | 2023-06-09 |
| A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Rucaparib - Metastatic Castration Resistant Prostate Cancer | Phase 2 | Completed | pharmaand GmbH | 277 | 2017-02-15 | 2023-06-09 |
Showing 20 of 37. Sign in to see all of them.
Fallopian Tube Neoplasms (7) · Neoplasms (6) · Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (5) · Carcinoma, Ovarian Epithelial (4) · Neoplasm Metastasis (4) · Ovarian Neoplasms (4) · Colonic Neoplasms (3) · Neoplasms, Unknown Primary (3) · Recurrence (3) · Carcinoma, Transitional Cell (2) · Lung Neoplasms (2) · Adenocarcinoma of Lung (1) · Carcinoma, Endometrioid (1) · Cholangiocarcinoma (1)
rucaparib (10) · Carboplatin (4) · Paclitaxel (4) · Abiraterone Acetate (3) · Bevacizumab (3) · Cisplatin (3) · enzalutamide (3) · olaparib (3) · pembrolizumab (3) · Capecitabine (2) · Gemcitabine (2) · High-Throughput Nucleotide Sequencing (2) · Nivolumab (2) · atezolizumab (2) · inavolisib (2)
United States (29) · Italy (11) · Spain (11) · United Kingdom (11) · Canada (8) · France (8) · Germany (8) · Israel (8) · Australia (7) · Belgium (5) · Denmark (5) · Ireland (4) · South Korea (4) · Brazil (3) · Czechia (3)
Barbara Gitlitz, MD (1) · Bryan P Schneider, MD (1) · Domenica Lorusso, Prof. (1) · Fangjian Zhou, M.D. (1) · Funda Meric-Bernstam, MD (1) · Gary Palmer, MD (1) · Heidi Giordano (1) · Howard A. Burris, III, MD (1) · In Ae Kim, MD. Ph.D (1) · Jason Sicklick, MD and Razelle Kurzrock, MD (1) · Jenna Canzoniero, MD (1) · Jhanelle Gray, MD (1) · Johann de Bono, M.D., Ph.D. (1) · John M Maris, MD (1)
PMID 35397664, PMID 31685558, PMID 32203306, PMID 35170751, PMID 36898948, PMID 10623700, PMID 10628376, PMID 10793106, PMID 11309294, PMID 11331762, PMID 11459964, PMID 11533692, PMID 12205100, PMID 12217790, PMID 12241653, PMID 12460789, PMID 14701743, PMID 15327776, PMID 15367671, PMID 15665856, PMID 1581961, PMID 15829966, PMID 15829967, PMID 15905196, PMID 16239238, PMID 16357170, PMID 16394300, PMID 16912188, PMID 16946210, PMID 17714938, PMID 18024865, PMID 18268546, PMID 18955455, PMID 19049966, PMID 19553641, PMID 19779458, PMID 20551068, PMID 20606085, PMID 20609467, PMID 20609468, PMID 21720365, PMID 21862407, PMID 22203755, PMID 22204724, PMID 22204725, PMID 22237781, PMID 22452356, PMID 22576213, PMID 22711857, PMID 22912389
2016 (4), 2017 (3), P30CA014089 (1)